

Therapeutics Advisory Group Update - Issue 29 – March 2024

All recommendations discussed at the **March** TAG and D+TC meetings and ratified by the Planned Care and Medicines Management Working Group on behalf of the ICB – **March 2024**. Please share within your organisation as appropriate

Commissioning Summary

Commissioning Review – Cough Suppressants – Codeine and Pholcodine	<ul style="list-style-type: none"> Codeine amended to Double Red (last resort once other options failed) Pholcodine amended to BLACK – Not commissioned. No prescribing in primary or secondary care
Commissioning Review - Magnesium Lactate MR caplets (Mag-Tab SR)	<ul style="list-style-type: none"> Switch to Magnalac SR 84mg tabs – best value ADVICE - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation
Commissioning Review - Ketogenic Diet Therapy prescriptions (KDT)	<ul style="list-style-type: none"> Products will be given an ADVICE classification – managed by tertiary epilepsy service at Addenbrookes
Safety Update - MHRA Valproate alert update – work in progress	<ul style="list-style-type: none"> Work ongoing to manage risk to patients Pathway in development Commissioning agreements to be reviewed in due course Referral process to be confirmed
Pathway Review - Ophthalmology Summary	<ul style="list-style-type: none"> High-cost drug ophthalmology overview for nAMD, DMO, BRVO, CRVO, CNV & non-infectious uveitis To use 'best value' preparations
Pathway Review - Hypersalivation	<ul style="list-style-type: none"> Addition of Assicco tablets to both adults and paediatrics Glycopyrronium preparations amended to ADVICE Glycobromag to remain as 'best value' option
Pathways transferred to new template in preparation for publication on KNoW <ul style="list-style-type: none"> Overactive bladder TA607 Rivaroxaban Primary Care Prescribing Advice for Lipid Management in Secondary Prevention AND Information for Prescribing and Management of Inclisiran 	

Feedback from Formulary and Clinical Groups

Updates from Respiratory Medicines Optimisation Group:

- Beclu (beclometasone dipropionate)** 100 micrograms per actuation pMDI and Beclu (beclometasone dipropionate) 200 micrograms per actuation pMDI – **GREEN - Drugs that can be initiated by Prescriber in Primary Care.**
- Easychamber** Spacers – **GREEN - Drugs that can be initiated by Prescriber in Primary Care.**
- GoResp® Digihaler®** (budesonide/formoterol) 160mcg/4.5mcg inhalation powder and **GoResp Digihaler** (budesonide/formoterol) 320mcg/9mcg inhalation powder – **BLUE - NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required**

Shared Care Updates

<ul style="list-style-type: none"> • Mycophenolate Mofetil for the treatment of autoimmune conditions 	<ul style="list-style-type: none"> • Amended to monitoring Level 2
<ul style="list-style-type: none"> • Mycophenolate mofetil / Mycophenolic acid for adult solid organ transplant patients • Sirolimus for adult solid organ transplant patients • Tacrolimus in adult solid organ transplant patients 	<ul style="list-style-type: none"> • Amended from 'renal' to 'solid organ transplant'
<ul style="list-style-type: none"> • Azathioprine in autoimmune diseases • Tacrolimus in ulcerative colitis • Sulfasalazine in the treatment of inflammatory arthritis and inflammatory bowel disease • Mercaptopurine in ulcerative colitis & Crohn's disease • Methotrexate oral and subcutaneous for various indications 	<ul style="list-style-type: none"> • Transferred to new template in preparation for publication on KNoW

NICE Guidance – acknowledged by the TAG

[NG33 – January 2016, updated February 2024 - Tuberculosis](#)

NICE Technology Appraisals – NHS England Commissioning Responsibility

<p>TA949 – February 2024 - Belumosudil (Rezurock®) for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over</p>	<p>RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care</p>
<p>TA950 – February 2024 - Nivolumab–relatlimab (Opdualag®) for untreated unresectable or metastatic melanoma in people 12 years and over</p>	
<p>TA951 – February 2024 - Olaparib (Lynparza®) with abiraterone for untreated hormone-relapsed metastatic prostate cancer</p>	
<p>TA952 – February 2024 - Talazoparib (Talzenna®) for treating HER2-negative advanced breast cancer with germline BRCA mutations</p>	

Knowledge NoW

- Knowledge NoW is now live and can be accessed [here](#) Please send any comments/queries to the inbox with '**KNoW**' in the subject line - nwcb.medsqueries@nhs.net
- Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates

Useful Information

Next meeting	Wednesday 1st May 2024
Deadline for agenda submissions	Tuesday 23rd April 2024